MX2024002335A - Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales. - Google Patents

Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.

Info

Publication number
MX2024002335A
MX2024002335A MX2024002335A MX2024002335A MX2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A MX 2024002335 A MX2024002335 A MX 2024002335A
Authority
MX
Mexico
Prior art keywords
relaxin
vasopressin
administration
compositions
individual
Prior art date
Application number
MX2024002335A
Other languages
English (en)
Spanish (es)
Inventor
Guido Magni
Original Assignee
River 2 Renal Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by River 2 Renal Corp filed Critical River 2 Renal Corp
Publication of MX2024002335A publication Critical patent/MX2024002335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024002335A 2021-08-23 2022-08-22 Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales. MX2024002335A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US202263332994P 2022-04-20 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (1)

Publication Number Publication Date
MX2024002335A true MX2024002335A (es) 2024-05-23

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002335A MX2024002335A (es) 2021-08-23 2022-08-22 Combinacion de analogos de relaxina y vasopresina para el tratamiento de trastornos y afecciones renales.

Country Status (7)

Country Link
US (1) US20240400638A1 (cg-RX-API-DMAC10.html)
EP (1) EP4392440A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532403A (cg-RX-API-DMAC10.html)
AU (1) AU2022334113A1 (cg-RX-API-DMAC10.html)
CA (1) CA3229783A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024002335A (cg-RX-API-DMAC10.html)
WO (1) WO2023028008A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199821A (en) * 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022294A1 (en) * 2012-07-31 2014-02-06 Novartis Ag Treating inflammation using serelaxin
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MY199821A (en) * 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use

Also Published As

Publication number Publication date
JP2024532403A (ja) 2024-09-05
WO2023028008A3 (en) 2023-10-26
EP4392440A4 (en) 2025-07-30
US20240400638A1 (en) 2024-12-05
EP4392440A2 (en) 2024-07-03
CA3229783A1 (en) 2023-03-02
AU2022334113A1 (en) 2024-03-14
WO2023028008A2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2024001205A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso.
AR134152A2 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
JOP20200137A1 (ar) نظائر إنكريتين واستخداماتها
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CO2022018715A2 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
MX2020002191A (es) Agentes antivirales contra la hepatitis b.
CR20160093A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
MX2021004566A (es) Compuestos terapeuticos.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
WO2023028008A3 (en) Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
MX2020002156A (es) Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2017002605A1 (es) Derivados de indol
CL2020002369A1 (es) Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.